Skip to main content
. 2024 Jul 5;7(7):e2419142. doi: 10.1001/jamanetworkopen.2024.19142

Table 4. Univariable and Multivariable Cox Proportional Hazards Regression Models for Overall Survival.

Characteristics Univariable analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
MSI testing
No 1 [Reference] NA 1 [Reference] NA
Yes 0.62 (0.60-0.63) <.001 0.93 (0.91-0.96) <.001
KRAS testing
No 1 [Reference] NA 1 [Reference] NA
Yes 0.71 (0.69-0.72) <.001 0.97 (0.95-1.00) .03
Age, y
18-49 1 [Reference] NA 1 [Reference] NA
50-59 1.16 (1.12-1.20) <.001 1.06 (1.02-1.10) .007
60-69 1.43 (1.38-1.49) <.001 1.16 (1.12-1.21) <.001
70-79 1.90 (1.83-1.97) <.001 1.30 (1.24-1.35) <.001
Sex
Male 1 [Reference] NA 1 [Reference] NA
Female 0.96 (0.94-0.98) <.001 0.98 (0.96-1.00) .07
Ethnicitya
Non-Hispanic 1 [Reference] NA 1 [Reference] NA
Hispanic 0.83 (0.79-0.87) <.001 0.84 (0.79-0.88) <.001
CCI
0 1 [Reference] NA 1 [Reference] NA
1 1.18 (1.15-1.21) <.001 1.08 (1.05-1.11) <.001
≥2 1.60 (1.54-1.66) <.001 1.28 (1.24-1.34) <.001
Grade
Well-differentiated 1 [Reference] NA 1 [Reference] NA
Moderately differentiated 1.03 (0.97-1.08) .40 1.12 (1.06-1.18) <.001
Poorly differentiated 1.59 (1.50-1.69) <.001 1.80 (1.70-1.91) <.001
Insurance type
Private 1 [Reference] NA 1 [Reference] NA
No insurance 1.38 (1.31-1.45) <.001 1.20 (1.14-1.26) <.001
Medicaid 1.26 (1.21-1.31) <.001 1.14 (1.09-1.18) <.001
Medicare or otherb 1.56 (1.52-1.60) <.001 1.13 (1.10-1.16) <.001
Unknown 1.32 (1.19-1.47) <.001 1.08 (0.98-1.20) .14
Educational level in area of residence, %c
≥17.6 1 [Reference] NA 1 [Reference] NA
10.9-17.5 1.03 (1.00-1.06) .11 0.99 (0.96-1.03) .62
6.3-10.8 0.97 (0.94-1.00) .02 0.98 (0.94-1.02) .29
Unknown 1.02 (0.91-1.15) .69 1.06 (0.69-1.62) .78
Facility type with CP
Academic 1 [Reference] NA 1 [Reference] NA
Community 1.24 (1.19-1.29) <.001 1.07 (1.02-1.12) .003
Comprehensive 1.20 (1.17-1.23) <.001 1.13 (1.10-1.17) <.001
Integrated network 1.16 (1.13-1.20) <.001 1.13 (1.09-1.16) <.001
Median household income, US$
≥63 333 1 [Reference] NA 1 [Reference] NA
50 354-63 332 1.09 (1.06-1.12) <.001 1.05 (1.01-1.08) .007
40 227-50 353 1.16 (1.12-1.19) <.001 1.08 (1.04-1.12) <.001
<40 277 1.20 (1.17-1.24) <.001 1.10 (1.05-1.15) <.001
Unknown 1.13 (1.01-1.26) .04 0.97 (0.65-1.46) .89
Year of diagnosis
2010 1 [Reference] NA 1 [Reference] NA
2011 0.96 (0.92-1.00) .07 0.97 (0.93-1.01) .18
2012 0.93 (0.89-0.97) <.001 0.92 (0.88-0.96) <.001
2013 0.95 (0.91-0.99) .01 0.96 (0.92-1.00) .07
2014 0.96 (0.92-1.00) .05 0.98 (0.94-1.02) .31
2015 0.91 (0.87-0.95) <.001 0.93 (0.89-0.97) .002
2016 0.86 (0.82-0.90) <.001 0.91 (0.87-0.95) <.001
2017 0.81 (0.77-0.85) <.001 0.83 (0.79-0.87) <.001
Immunotherapy
Not administered 1 [Reference] NA 1 [Reference] NA
Administered 0.65 (0.63-0.67) <.001 0.85 (0.82-0.87) <.001
Unknown 0.85 (0.68-1.05) .13 0.97 (0.77-1.21) .76
Chemotherapy
Not administered 1 [Reference] NA 1 [Reference] NA
Administered 0.31 (0.30-0.32) <.001 0.37 (0.36-0.38) <.001
Unknown 0.41 (0.38-0.44) <.001 0.49 (0.45-0.52) <.001
Lung metastasis at presentation
Absent 1 [Reference] NA 1 [ Reference] NA
Present 1.33 (1.30-1.37) <.001 1.16 (1.13-1.19) <.001
Unknown 1.51 (1.39-1.64) <.001 1.07 (0.98-1.17) .14
Liver metastasis at presentation
Absent 1 [Reference] NA 1 [Reference] NA
Present 1.10 (1.07-1.13) <.001 1.27 (1.23-1.30) <.001
Unknown 1.52 (1.33-1.73) <.001 1.09 (0.95-1.26) .21
Surgery primary site
No 1 [Reference] NA 1 [Reference] NA
Yes 0.46 (0.45-0.47) <.001 0.53 (0.52-0.55) <.001
Unknown 0.54 (0.39-0.74) <.001 0.58 (0.42-0.82) .002
Surgery nonprimary site
No 1 [Reference] NA 1 [Reference] NA
Yes 0.56 (0.54-0.58) <.001 0.81 (0.79-0.84) <.001
Unknown 0.56 (0.38-0.83) .003 0.78 (0.53-1.15) .21
Area of residence
Metropolitan 1 [Reference] NA 1 [Reference] NA
Urban 1.11 (1.08-1.15) <.001 1.04 (1.00-1.08) .07
Rural 1.16 (1.06-1.26) .001 1.11 (1.02-1.22) .02
Facility locationd
New England 1 [Reference] NA 1 [Reference] NA
Middle Atlantic 0.91 (0.86-0.96) .001 0.85 (0.80-0.90) <.001
South Atlantic 1.03 (0.98-1.09) .28 1.02 (0.96-1.08) .56
East North Central 1.08 (1.02-1.14) .01 1.08 (1.02-1.14) .008
East South Central 1.07 (1.00-1.15) .04 1.03 (0.97-1.11) .35
West North Central 1.03 (0.97-1.10) .35 1.06 (1.00-1.13) .07
West South Central 0.96 (0.90-1.02) .21 0.84 (0.79-0.89) <.001
Mountain 1.01 (0.94-1.09) .73 0.94 (0.87-1.00) .07
Pacific 0.98 (0.93-1.04) .50 0.98 (0.92-1.04) .45
Travel distance, miles
≤5 1 [Reference] NA 1 [Reference] NA
5.1-10 0.94 (0.92-0.97) <.001 0.98 (0.95-1.01) .22
10.1-25 0.90 (0.87-0.93) <.001 0.99 (0.97-1.03) .75
>25 0.90 (0.87-0.93) <.001 0.99 (0.96-1.03) .71

Abbreviations: CCI, Charlson Comorbidity Index (range: 0-25, with the highest score indicating a higher number of comorbidities); CP, cancer program; HR, hazard ratio; MSI, microsatellite instability; NA, not applicable.

a

Ethnicity data obtained from the NCDB were self-identified in the patients’ medical records. Hispanic ethnicity includes Mexican, Puerto Rican, Cuban, South or Central American (except Brazil), Dominican Republic, or Spanish origin.

b

Other insurance type includes other governmental insurance.

c

Educational level was assessed at the zip code level based on the percentage of adult residents without a high school diploma.

d

US Census division.